JP2015523328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523328A5 JP2015523328A5 JP2015511443A JP2015511443A JP2015523328A5 JP 2015523328 A5 JP2015523328 A5 JP 2015523328A5 JP 2015511443 A JP2015511443 A JP 2015511443A JP 2015511443 A JP2015511443 A JP 2015511443A JP 2015523328 A5 JP2015523328 A5 JP 2015523328A5
- Authority
- JP
- Japan
- Prior art keywords
- ctla
- polypeptide
- amino acid
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 21
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 21
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 21
- 229920001184 polypeptide Polymers 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 238000000034 method Methods 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 102000054189 human CD80 Human genes 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 2
- 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 102000049849 human CD86 Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261645686P | 2012-05-11 | 2012-05-11 | |
| US61/645,686 | 2012-05-11 | ||
| PCT/US2013/030179 WO2013169338A1 (en) | 2012-05-11 | 2013-03-11 | Ctla-4 variants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015523328A JP2015523328A (ja) | 2015-08-13 |
| JP2015523328A5 true JP2015523328A5 (https=) | 2016-03-31 |
| JP6228971B2 JP6228971B2 (ja) | 2017-11-08 |
Family
ID=49551120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511443A Active JP6228971B2 (ja) | 2012-05-11 | 2013-03-11 | Ｃｔｌａ−４バリアント |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9884902B2 (https=) |
| EP (2) | EP3207938B1 (https=) |
| JP (1) | JP6228971B2 (https=) |
| KR (1) | KR102133060B1 (https=) |
| CN (2) | CN107540742B (https=) |
| AU (1) | AU2013260172B2 (https=) |
| BR (1) | BR112014026718B1 (https=) |
| CA (1) | CA2868748C (https=) |
| DK (1) | DK3207938T3 (https=) |
| ES (1) | ES2777778T3 (https=) |
| HK (1) | HK1209644A1 (https=) |
| HU (1) | HUE048925T2 (https=) |
| MX (2) | MX355234B (https=) |
| PL (1) | PL3207938T3 (https=) |
| RU (1) | RU2671465C2 (https=) |
| SG (2) | SG11201405968SA (https=) |
| WO (1) | WO2013169338A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4119857A1 (de) | 1991-06-17 | 1992-12-24 | Basf Lacke & Farben | Ueberzugsmittel auf der basis von carboxylgruppenhaltigen polymeren und epoxidharzen |
| WO2013169338A1 (en) * | 2012-05-11 | 2013-11-14 | Medimmune, Llc | Ctla-4 variants |
| US9926365B2 (en) * | 2012-06-29 | 2018-03-27 | Bristol-Myers Squibb Company | Methods for reducing glycoprotein aggregation |
| US9944689B2 (en) * | 2013-03-07 | 2018-04-17 | The General Hospital Corporation | Human CTLA4 mutants and use thereof |
| WO2015113494A1 (zh) * | 2014-01-28 | 2015-08-06 | 北京韩美药品有限公司 | 双功能融合蛋白及其制备方法和用途 |
| ES2789351T3 (es) | 2015-01-13 | 2020-10-26 | Hope City | Máscaras de enlace peptídico de proteínas de unión a CTLA4 |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| CN121159719A (zh) | 2015-04-17 | 2025-12-19 | 高山免疫科学股份有限公司 | 具有可调的亲和力的免疫调节蛋白 |
| CN108137659B (zh) | 2015-08-21 | 2021-11-26 | 汉阳大学校产学协力团 | 具有预防或治疗中枢神经系统疾病作用的肽和包含其作为活性成分的药物组合物 |
| WO2017034244A1 (ko) * | 2015-08-21 | 2017-03-02 | 한양대학교 산학협력단 | 중추신경계 질환에 대한 예방 또는 치료효과를 갖는 펩타이드 및 이를 유효성분으로 하는 중추신경계 질환 예방 및 치료용 약학적 조성물 |
| US11351224B2 (en) | 2015-08-21 | 2022-06-07 | Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) | Pharmaceutical composition for preventing and treating transplant rejection |
| CN108513576A (zh) * | 2015-09-14 | 2018-09-07 | 高山免疫科学股份有限公司 | 可调变体免疫球蛋白超家族结构域和工程改造的细胞治疗 |
| IL260021B (en) | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| KR101918456B1 (ko) * | 2015-12-15 | 2018-11-16 | 앱클론(주) | Cd80 및 cd86에 특이적으로 결합하는 항체 |
| MX2018012472A (es) | 2016-04-15 | 2019-08-12 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
| WO2017181152A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| SG11201907769XA (en) | 2017-03-16 | 2019-09-27 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
| KR20190141146A (ko) | 2017-03-16 | 2019-12-23 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Pd-l2 변이체 면역조절 단백질 및 그의 용도 |
| KR102840867B1 (ko) | 2017-05-24 | 2025-07-30 | 에이엘에스 테라피 디벨럽먼트 인스티튜트 | 치료용 항-cd40 리간드 항체 |
| JP7749319B2 (ja) * | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| BR112020007542A2 (pt) | 2017-10-18 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados |
| AU2019205273B2 (en) | 2018-01-03 | 2024-04-04 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| WO2020088645A1 (en) | 2018-11-02 | 2020-05-07 | Beijing Vdjbio Co., Ltd. | Modified ctla4 and methods of use thereof |
| CA3120868A1 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| CN113645990B (zh) * | 2019-04-10 | 2025-01-24 | 肯塔基大学研究基金会 | 改良的前列腺凋亡反应-4(par-4)多肽及其生产和使用方法 |
| IL294114A (en) * | 2020-01-11 | 2022-08-01 | Univ Yale | Preparations and methods for the treatment, improvement and/or prevention of diseases or disorders caused by or related to dnase1 and/or dnase1l3 |
| HRP20240182T1 (hr) | 2020-03-26 | 2024-04-26 | Vanderbilt University | Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2) |
| AU2021252514B2 (en) * | 2020-04-06 | 2025-06-26 | Lung Biotechnology Pbc | Modular synthetic receptors and methods of use |
| AU2021262609A1 (en) | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| EP4146684A2 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| CN112661865B (zh) * | 2020-12-31 | 2026-04-03 | 厚朴生物科技（苏州）有限公司 | 针对新型冠状病毒的疫苗以及其应用 |
| EP4392156A4 (en) * | 2021-10-08 | 2025-06-25 | Kashiv Biosciences, LLC | Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography |
| AU2022359021A1 (en) * | 2021-10-08 | 2024-05-02 | Kashiv Biosciences, Llc | Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography |
| AU2022414315A1 (en) * | 2021-12-17 | 2024-07-25 | Kashiv Biosciences, Llc | An improved assay method for determining the potency of recombinant protein |
| TW202342510A (zh) | 2022-02-18 | 2023-11-01 | 英商Ｒｑ生物科技有限公司 | 抗體 |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2580812A1 (en) | 1991-06-27 | 1993-01-07 | Bristol-Myers Squibb Company | Ctla4 receptor, fusion proteins containing it and uses thereof |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| CA2257861A1 (en) * | 1996-06-14 | 1997-12-18 | Smithkline Beecham Corporation | Hexameric fusion proteins and uses therefor |
| CN101255192A (zh) * | 2000-05-26 | 2008-09-03 | 布里斯托尔-迈尔斯斯奎布公司 | 可溶性ctla4突变体分子及其应用 |
| US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| WO2007007654A1 (ja) | 2005-07-07 | 2007-01-18 | Toshiba Lighting & Technology Corporation | 放電灯点灯装置および電球形蛍光ランプ |
| GB0620934D0 (en) * | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
| EP2612867A1 (en) * | 2007-11-01 | 2013-07-10 | Perseid Therapeutics LLC | Immunosuppressive polypeptides and nucleic acids |
| HUE030100T2 (en) | 2010-02-19 | 2017-04-28 | Xencor Inc | New CTLA4-IG immunoadhesins |
| CN106432474A (zh) | 2010-03-12 | 2017-02-22 | 艾伯维生物医疗股份有限公司 | Ctla4蛋白和其用途 |
| WO2013169338A1 (en) * | 2012-05-11 | 2013-11-14 | Medimmune, Llc | Ctla-4 variants |
-
2013
- 2013-03-11 WO PCT/US2013/030179 patent/WO2013169338A1/en not_active Ceased
- 2013-03-11 SG SG11201405968SA patent/SG11201405968SA/en unknown
- 2013-03-11 KR KR1020147031064A patent/KR102133060B1/ko active Active
- 2013-03-11 US US14/399,685 patent/US9884902B2/en active Active
- 2013-03-11 MX MX2014013092A patent/MX355234B/es active IP Right Grant
- 2013-03-11 HU HUE17163638A patent/HUE048925T2/hu unknown
- 2013-03-11 CN CN201710735648.7A patent/CN107540742B/zh active Active
- 2013-03-11 PL PL17163638T patent/PL3207938T3/pl unknown
- 2013-03-11 CA CA2868748A patent/CA2868748C/en active Active
- 2013-03-11 ES ES17163638T patent/ES2777778T3/es active Active
- 2013-03-11 RU RU2014150092A patent/RU2671465C2/ru active
- 2013-03-11 DK DK17163638.4T patent/DK3207938T3/da active
- 2013-03-11 AU AU2013260172A patent/AU2013260172B2/en active Active
- 2013-03-11 CN CN201380024763.3A patent/CN104302309B/zh active Active
- 2013-03-11 EP EP17163638.4A patent/EP3207938B1/en active Active
- 2013-03-11 HK HK15110585.3A patent/HK1209644A1/xx unknown
- 2013-03-11 BR BR112014026718-9A patent/BR112014026718B1/pt active IP Right Grant
- 2013-03-11 MX MX2018003741A patent/MX385969B/es unknown
- 2013-03-11 SG SG10201609447XA patent/SG10201609447XA/en unknown
- 2013-03-11 EP EP13787673.6A patent/EP2863936A4/en not_active Withdrawn
- 2013-03-11 JP JP2015511443A patent/JP6228971B2/ja active Active
-
2017
- 2017-12-21 US US15/850,990 patent/US20180208639A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015523328A5 (https=) | ||
| JP2011508604A5 (https=) | ||
| Bermudez-Humaran et al. | An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci | |
| IL275307A (en) | SYNTAC polypeptides and their uses | |
| JP2016532693A5 (https=) | ||
| HRP20190689T1 (hr) | Muteini suznog lipokalina koji vežu il-4r alfa | |
| EP4609876A3 (en) | Anti-human papillomavirus 16 e7 t cell receptors | |
| EP4647442A3 (en) | T cell receptors recognizing mutated p53 | |
| JP2015532654A5 (https=) | ||
| WO2007130455A3 (en) | Compositions and methods for treatment of non-hodgkins lymphoma | |
| JP2018506286A5 (https=) | ||
| JP2019522465A5 (https=) | ||
| JP2016156828A5 (https=) | ||
| JP2013519721A5 (https=) | ||
| JP2012095652A5 (https=) | ||
| JP2018510622A5 (https=) | ||
| JP2016526909A5 (https=) | ||
| JP2010519176A5 (https=) | ||
| WO2011028344A3 (en) | Interleukin-1 receptor antagonist compositions and methods of making and using same | |
| JP2015511637A5 (https=) | ||
| CA2759583A1 (en) | A tuberculosis tb vaccine to prevent reactivation | |
| TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
| JP2009511000A5 (https=) | ||
| JP2014529399A5 (https=) | ||
| JP2012516140A5 (https=) |